Clarity Pharmaceuticals Receives AU$9.8 Million R&D Tax Incentive Refund to Advance Cancer Therapy Pipeline
Clarity Pharmaceuticals Limited (ASX: CU6) has received approximately AU$9.8 million under the Australian Federal Government’s Research and Development Tax Incentive program, strengthening the Company’s funding position as it progresses development of its Targeted Copper Theranostic (TCT) platform for cancer treatment. The refund recognises eligible Australian R&D activities undertaken during FY25 and provides valuable non-dilutive capital to support ongoing clinical and product development initiatives.
The additional funding is expected to accelerate advancement of Clarity’s radiopharmaceutical programs, including SAR-bisPSMA and SARTATE, which are generating encouraging outcomes in later-stage clinical trials. Management highlighted that the incentive extends the Company’s cash runway while also supporting exploration of novel cancer targets with significant unmet medical need.
Clarity continues to position itself as a leader in next-generation radiopharmaceuticals through its proprietary SAR Technology Platform, targeting improved precision and treatment outcomes across multiple oncology indications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Clarity Pharmaceuticals Receives AU$9.8 Million R&D Tax Incentive Refund to Advance Cancer Therapy Pipeline
Clarity Pharmaceuticals Limited (ASX: CU6) has received approximately AU$9.8 million under the Australian Federal Government’s Research and Development Tax Incentive program, strengthening the Company’s funding position as it progresses development of its Targeted Copper Theranostic (TCT) platform for cancer treatment. The refund recognises eligible Australian R&D activities undertaken during FY25 and provides valuable non-dilutive capital to support ongoing clinical and product development initiatives.
The additional funding is expected to accelerate advancement of Clarity’s radiopharmaceutical programs, including SAR-bisPSMA and SARTATE, which are generating encouraging outcomes in later-stage clinical trials. Management highlighted that the incentive extends the Company’s cash runway while also supporting exploration of novel cancer targets with significant unmet medical need.
Clarity continues to position itself as a leader in next-generation radiopharmaceuticals through its proprietary SAR Technology Platform, targeting improved precision and treatment outcomes across multiple oncology indications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au